Citius Pharmaceuticals, Inc.

Equities

CTXR

US17322U2078

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:29:47 05/06/2024 am IST			5-day change	1st Jan Change
0.6369 ^USD	-4.28%		+0.79%	-15.81%

21/05	Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	CI
14/05	Citius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI

Citius Pharmaceuticals, Inc. Announces Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls

November 05, 2021 at 06:45 pm IST

Citius Pharmaceuticals, Inc. announced the appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls (CMC). Mr. Creighton will be responsible for the global strategic regulatory and manufacturing development plans for Citius's five pipeline programs. Kelly Creighton, PhDjoins Citius from Clinipace Worldwide.

Latest news about Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	21/05	CI
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	15/05	CI
Citius Pharmaceuticals Launches $15 Million Offering	26/04	MT
Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	11/04	CI
Citius Pharmaceuticals, Inc. Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	19/03	CI
Citius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	15/02	CI
Sector Update: Health Care Stocks Gain Late Afternoon	15/02	MT
Citius Pharmaceuticals Resubmits Application for Lymphoma Treatment	15/02	MT
Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir	14/02	CI
North American Morning Briefing : Stock Futures Extend Losses as FOMC Minutes Awaited	03/01	DJ
Citius Pharmaceuticals Completes Enrollment in Phase 3 Trial for Mino-Lok	03/01	MT
Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters	02/01	CI
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	30/12	CI
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	20/12	DJ
Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR? in Combination with Checkpoint Inhibitor	31/23/31	CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	25/23/25	MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading	24/23/24	MT
Citius Pharmaceuticals to Merge Oncology Unit with TenX Keane Acquisition; Citius Shares Rise	24/23/24	MT
Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee	26/23/26	CI
Sector Update: Health Care Stocks Slipping Late Friday8 Afternoon	09/23/09	MT
Sector Update: Health Care	09/23/09	MT
Citius Pharmaceuticals Says No Additional Trials Required to Support Biologics License Application for Lymphir	08/23/08	MT
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR	08/23/08	CI
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	15/23/15	CI
Sector Update: Health Care Stocks Decline Thursday	11/23/11	MT

Chart Citius Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.6654 USD

Average target price

4 USD

Spread / Average Target

+501.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CITIUS PHARMACEUTICALS, INC.	-15.81%	12Cr
MODERNA, INC.	+46.19%	5.67TCr
IQVIA HOLDINGS INC.	-6.14%	3.94TCr
LONZA GROUP AG	+39.19%	3.9TCr
CELLTRION, INC.	-6.65%	2.69TCr
ICON PUBLIC LIMITED COMPANY	+12.33%	2.67TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.78%	1.9TCr
BIO-TECHNE CORPORATION	-0.35%	1.23TCr
UNITED THERAPEUTICS CORPORATION	+24.18%	1.23TCr
MEDPACE HOLDINGS, INC.	+28.38%	1.2TCr

Other Biotechnology & Medical Research